This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss
by Zacks Equity Research
Conatus (CNAT) reports narrower-than-expected loss in Q4 while revenues marginally fall short of estimates. However, the top line shows a massive year-over-year increase.
Merck to Pay $300M Upfront to Co-Develop Eisai's Cancer Drug
by Zacks Equity Research
Merck (MRK) is going to pay $300 million upfront to Japan's Eisai to jointly develop and commercialize the latter's pipeline candidate Lenvima.
Glaxo's Encouraging Asthma & HIV Data at Medical Meetings
by Zacks Equity Research
Glaxo (GSK) presents data from OSMO study on a new respiratory medicine, Nucala, and on INSPIRING, a phase IIIb study on investigational HIV candidate dolutegravir at medical conferences.
Aduro (ADRO) Q4 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Aduro (ADRO) reports narrower-than-expected loss in Q4. However, sales miss estimates and fall year over year on declining grant revenues.
What's in Store for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q4. However, the company's portfolio lacks an approved product and its revenue generation.
Amgen (AMGN) Gets CHMP Nod to Expand EU Label of Neulasta
by Zacks Equity Research
Amgen (AMGN) gains positive opinion from the CHMP to update the label of Neulasta to include Neulasta Onpro Kit, an innovative delivery system.
Aerie's (AERI) Q4 Loss Wider on Higher Operating Expenses
by Zacks Equity Research
Aerie (AERI) incurs a wider-than-expected loss in the fourth quarter due to higher operating expenses.
Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus
by Zacks Equity Research
Ophthotech (OPHT) reports better-than-expected fourth-quarter earnings but misses on sales. The company plans to use novel gene therapy to develop new treatments for ocular diseases.
Medicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/Y
by Zacks Equity Research
Medicines Company (MDCO) incurs wider-than-expected loss in the fourth quarter of 2017. Moreover, the top line declines year over year on low Angiomax sales.
Ligand (LGND) Q4 Earnings & Revenues Top, 2018 View Solid
by Zacks Equity Research
Ligand's (LGND) earnings and revenues beat estimates. The top line also rises year over year owing to higher royalty benefits. The company provides a strong 2018 guidance.
Teva's Problems Continue to Mount With No Relief in Sight
by Zacks Equity Research
Teva (TEVA) faces significant challenges including rapid erosion in sales of Copaxone and pricing erosion in the U.S. generics business.
Novartis Psoriasis Drug Cosentyx Positive in SCALP Study
by Zacks Equity Research
Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
by Zacks Equity Research
Data shows that AstraZeneca's (AZN) Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population.
Celgene Reports Positive Data on Dermatology Drug Otezla
by Zacks Equity Research
Celgene (CELG) is looking to expand dermatology drug Otezla's label and reported positive data from a late-stage study in patients with active Beh??et???s Disease.
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
by Zacks Equity Research
Roche (RHHBY) announces that it will acquire Flatiron Health to accelerate development and delivery of breakthrough drugs for cancer patients.
Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales
by Zacks Equity Research
Incyte (INCY) beat on revenues in the fourth quarter driven by an increase in Jakafi sales. The guidance for 2018 was also encouraging.
Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva
by Zacks Equity Research
Intercept (ICPT) missed on both earnings and revenues in the fourth quarter as Ocaliva sales were drab due to safety issues of the drug.
Roche's Rituxan Gets Priority Review for Label Expansion
by Zacks Equity Research
FDA accepts sBLA and grants priority review for Roche Group's (RHHBY) leukemia drug Rituxan.
Lilly's Taltz Positive in Phase III Label Expansion Study
by Zacks Equity Research
Lilly's (LLY) psoriasis drug, Taltz, meets all endpoints in a phase III study evaluating it in patients with ankylosing spondylitis.
Teva Stock Falls as Novartis Brings Another Copaxone Generic
by Zacks Equity Research
Teva's (TEVA) shares fall as Novartis launches the second generic version of the 40 mg formulation of Copaxone
Generic Drugmakers to Dump as Teva's Woes Continue in 2018
by Zacks Equity Research
The generic industry is facing several challenges pulling down several companies including Teva (TEVA).
Intercept Starts OCA Trial for NASH Patients With Cirrhosis
by Zacks Equity Research
Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.
Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?
by Zacks Equity Research
Growth in Jakafi sales are likely to help Incyte (INCY) to beat on earnings in Q4.
The Zacks Analyst Blog Highlights: Novartis, BP and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, BP and Biogen